No link between type I interferon autoantibody positivity and adverse reactions to COVID-19 vaccines

No link between type I interferon autoantibody positivity and adverse reactions to COVID-19 vaccines

Abstract Type I interferons act as gatekeepers against viral infection, and autoantibodies that neutralize these signaling molecules have been associated with COVID-19 severity and adverse reactions to the live-attenuated yellow fever vaccine. On this background, we sought to examine whether autoant...

Full description

Bibliographic Details
Main Authors: Ahmet Yalcinkaya, Marco Cavalli, Axel Cederholm, Maribel Aranda-Guillén, Anish Behere, Hedvig Mildner, Tadepally Lakshmikanth, Laura Gonzalez, Constantin Habimana Mugabo, Anette Johnsson, Olov Ekwall, Olle Kämpe, Sophie Bensing, Petter Brodin, Pär Hallberg, Mia Wadelius, Nils Landegren
Format: Article
Language:English
Published: Nature Portfolio 2024-02-01
Series:npj Vaccines
Online Access:https://doi.org/10.1038/s41541-024-00829-9
Description
Summary:Abstract Type I interferons act as gatekeepers against viral infection, and autoantibodies that neutralize these signaling molecules have been associated with COVID-19 severity and adverse reactions to the live-attenuated yellow fever vaccine. On this background, we sought to examine whether autoantibodies against type I interferons were associated with adverse events following COVID-19 vaccination. Our nationwide analysis suggests that type I interferon autoantibodies were not associated with adverse events after mRNA or viral-vector COVID-19 vaccines.
ISSN:2059-0105

Similar Items